GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.
Nat Commun
; 14(1): 3274, 2023 06 06.
Artigo
em Inglês
| MEDLINE | ID: covidwho-20240984
ABSTRACT
SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based SARS-CoV-2 vaccine delivering full-length Spike and selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial evaluating GRT-R910 in previously vaccinated healthy older adults (NCT05148962). Primary endpoints of safety and tolerability were assessed. Most solicited local and systemic adverse events (AEs) following GRT-R910 dosing were mild to moderate and transient, and no treatment-related serious AEs were observed. The secondary endpoint of immunogenicity was assessed via IgG binding assays, neutralization assays, interferon-gamma ELISpot, and intracellular cytokine staining. Neutralizing antibody titers against ancestral Spike and variants of concern were boosted or induced by GRT-R910 and, contrasting to authorized vaccines, persisted through at least 6 months after the booster dose. GRT-R910 increased and/or broadened functional Spike-specific T cell responses and primed functional T cell responses to conserved non-Spike epitopes. This study is limited due to small sample size, and additional data from ongoing studies will be required to corroborate these interim findings.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
COVID-19
Tipo de estudo:
Estudo experimental
/
Estudo prognóstico
/
Ensaios controlados aleatorizados
Tópicos:
Vacinas
/
Variantes
Limite:
Idoso
/
Feminino
/
Humanos
/
Masculino
/
Meia-Idade
Idioma:
Inglês
Revista:
Nat Commun
Assunto da revista:
Biologia
/
Ciência
Ano de publicação:
2023
Tipo de documento:
Artigo
País de afiliação:
S41467-023-39053-9
Similares
MEDLINE
...
LILACS
LIS